STOCKHOLM, March 31, 2023 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced its management’s participation in the following investor conferences: The Guggenheim Genomic Medicines and Rare Disease Days Conference, which is…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.